Todd M Durell

Summary

Affiliation: Eli Lilly and Company
Country: USA

Publications

  1. ncbi Impact of race on efficacy and safety during treatment with olanzapine in schizophrenia, schizophreniform or schizoaffective disorder
    Virginia L Stauffer
    Lilly USA, LLC, Lilly Corporate Center, Indianapolis, IN 46285, USA
    BMC Psychiatry 10:89. 2010
  2. ncbi Prevalence of nonmedical methamphetamine use in the United States
    Todd M Durell
    Eli Lilly and Company, Lilly Research Laboratories, Indianapolis, IN 46285, USA
    Subst Abuse Treat Prev Policy 3:19. 2008
  3. ncbi Effects of open-label atomoxetine on African-American and Caucasian pediatric outpatients with attention-deficit/hyperactivity disorder
    Todd M Durell
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
    Ann Clin Psychiatry 21:26-37. 2009
  4. ncbi Relationship between African-American or Caucasian origin and outcomes in the olanzapine treatment of acute mania: a pooled analysis of three adult studies conducted in the United States of America
    Elisabeth K Degenhardt
    Lilly USA, LLC, Indianapolis, Indiana 46285, USA
    Int Clin Psychopharmacol 26:141-5. 2011
  5. ncbi Stimulant formulation and motivation for nonmedical use of prescription attention-deficit/hyperactivity disorder medications in a college-aged population
    Himanshu P Upadhyaya
    Eli Lilly and Company and or one of its subsidiaries, Lilly Research Laboratories, Indianapolis, Indiana 46285, USA
    Am J Addict 19:569-77. 2010

Collaborators

Detail Information

Publications5

  1. ncbi Impact of race on efficacy and safety during treatment with olanzapine in schizophrenia, schizophreniform or schizoaffective disorder
    Virginia L Stauffer
    Lilly USA, LLC, Lilly Corporate Center, Indianapolis, IN 46285, USA
    BMC Psychiatry 10:89. 2010
    ..To examine potential differences in efficacy and safety of treatment with olanzapine in patients with schizophrenia of white and black descent...
  2. ncbi Prevalence of nonmedical methamphetamine use in the United States
    Todd M Durell
    Eli Lilly and Company, Lilly Research Laboratories, Indianapolis, IN 46285, USA
    Subst Abuse Treat Prev Policy 3:19. 2008
    ..The goal of the current study was to use a relatively inexpensive methodology to examine the prevalence and demographic correlates of nonmedical methamphetamine use in the United States...
  3. ncbi Effects of open-label atomoxetine on African-American and Caucasian pediatric outpatients with attention-deficit/hyperactivity disorder
    Todd M Durell
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
    Ann Clin Psychiatry 21:26-37. 2009
    ..Data on the management of attention-deficit/hyperactivity disorder (ADHD) in African-American children and adolescents are limited...
  4. ncbi Relationship between African-American or Caucasian origin and outcomes in the olanzapine treatment of acute mania: a pooled analysis of three adult studies conducted in the United States of America
    Elisabeth K Degenhardt
    Lilly USA, LLC, Indianapolis, Indiana 46285, USA
    Int Clin Psychopharmacol 26:141-5. 2011
    ....
  5. ncbi Stimulant formulation and motivation for nonmedical use of prescription attention-deficit/hyperactivity disorder medications in a college-aged population
    Himanshu P Upadhyaya
    Eli Lilly and Company and or one of its subsidiaries, Lilly Research Laboratories, Indianapolis, Indiana 46285, USA
    Am J Addict 19:569-77. 2010
    ..Those using extended release (ER) stimulant formulations were less likely to endorse "staying awake" as a reason for NMU compared to those using immediate release (IR) stimulant formulations.?..